Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-12 06:04 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
A Study of TCD601 (Siplizumab) in Newly Diagnosed Adult Amyotrophic Lateral Sclerosis (ALS) Patients
NCT06453668 · ITB-Med LLC · PHASE1 · terminated · last registry update 2026-07-17 · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “The Sponsor has decided to terminate study early due to significant enrolment challenges since restarting the study in Dec 2025. The Sponsor is concerned that the study is not feasible and ultimately the objectives of the study cannot be met.” | – | Registry record, ITB-Med LLC |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against CD2 within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2026-11-04Results posted on the registry: ITB-Med LLC, TCD601 (NCT04803006)
- 2026-11-04Also stopped (terminated): ITB-Med LLC, TCD601 (NCT04803006)
- 2026-07-28Results posted on the registry: National Institute of Allergy and Infectious Diseases (NIAID), Siplizumab (NCT05574335)
- 2026-07-28Also stopped (terminated): National Institute of Allergy and Infectious Diseases (NIAID), Siplizumab (NCT05574335)
- 2026-07-13Also stopped (terminated): ITB-Med LLC, TCD601 (NCT04803058)
- 2026-06-10Also stopped (terminated): Columbia University, Siplizumab + Cyclophosphamide 50mg (NCT06078696)
- 2026-03-12Results posted on the registry: ITB-Med LLC, TCD601 + Tacrolimus (TAC) (NCT06365437)
- 2026-03-12Also stopped (terminated): ITB-Med LLC, TCD601 + Tacrolimus (TAC) (NCT06365437)
- 2026-02-27Results posted on the registry: Columbia University, Siplizumab + Cyclophosphamide 50mg (NCT06078696)
- 2025-08-14Also stopped (terminated): ITB-Med LLC, TCD601 (NCT06025110)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision